Market Newsdesk

Company Installing Coronavirus Neutralizing Air Purification System Across its 28 Ship Fleet

New Green Air Technology to Feature Continuous Active COVID Disinfection through Bi-polar Ionization in the Air and on Surfaces

MIAMI, Dec. 07, 2020 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“Norwegian” or the “Company”) today announces a partnership with AtmosAir Solutions to install continuous disinfection air purification systems across its 28 ship fleet for its three brands, Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises. The new air filtration system technology will feature continuous active COVID disinfection through bi-polar ionization in the air and on surfaces, an all-natural solution with no harmful chemicals, radiations or by-products. One of the advantages of the bi-polar ionization process is that it allows air purification to occur within the desired space, treating a larger volume of air, instead of relying on contaminants passing through the air handler unit to be cleaned.

Tests performed by Microchem Laboratory, one of the world’s preeminent laboratories for testing EPA- and FDA-registered sanitizing products, confirmed that the presence of coronavirus was reduced by 99.92% within 30 minutes of exposure to AtmosAir.

“While it is impossible to completely eliminate the risks associated with COVID-19, the AtmosAir technology is one of the many investments the Company is making to enhance its already rigorous health and safety standards,” said Robin Lindsay, executive vice president of Vessel Operations for Norwegian Cruise Line Holdings Ltd. “We are working diligently on our multi-layered strategy for health and safety and AtmosAir’s proven all-natural bi-polar ionization technology will add yet another layer of protection on board our ships.”

“We are proud to partner with Norwegian Cruise Line Holdings on making their fleet safer for their guests and crew members,” Steve Levine, President & CEO of AtmosAir Solutions. “In order to get everyone back to work and back to having fun, people need to know that the spaces they occupy are safe, and AtmosAir adds a significant layer of protection, giving people confidence in the air they breathe. We look forward to seeing their fleet back on the high seas.”

AtmosAir’s patented bi-polar ionization technology continually and proactively attacks coronavirus and other viruses, bacteria, spores and volatile organic compounds quickly and effectively in the air and on surfaces, rather than requiring the air to be filtered out first. The technology works by releasing ions through the HVAC system, and these ions bond with viruses, breaking down their cellular structure and rendering them harmless. AtmosAir is providing cleaner air using a safe, natural and environmentally friendly process and helping protect cruise ships, airports, casinos, sports facilities, educational institutions, commercial buildings and a host of other spaces where people live, work and enjoy themselves worldwide with more than 7,500 locations across the globe currently using this technology.

About Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company which operates the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands. With a combined fleet of 28 ships with approximately 59,150 berths, these brands offer itineraries to more than 490 destinations worldwide. The Company has nine additional ships scheduled for delivery through 2027.

About
AtmosAir
Solutions

AtmosAir Solutions of Fairfield, CT provides clean green indoor air technology for commercial buildings, health care, hospitals, assisted living, hotels, cruise lines, universities and sports facilities. The company’s patented bi-polar ionization technology is over 99% effective in neutralizing coronavirus. Tests performed by Microchem Laboratory, one of the world’s preeminent laboratories for testing sanitizing products registered by the EPA and FDA, confirmed that the presence of coronavirus was reduced by 99.92 percent within 30 minutes of exposure to the AtmosAir’s bi-polar ion technology. AtmosAir’s technology improves wellness, makes buildings more sustainable, reduces their operational costs and its proven air purification technology is a continuous disinfectant, removing airborne and surface contaminants from indoor spaces. With more than 7,500 installations worldwide, AtmosAir’s patented bi-polar ionization technology suppresses airborne and surface microbials and pathogens, including viruses, bacteria and mold, and reduces odors as well as unhealthy and irritating volatile organic compounds (VOCs). More information can be found at www.atmosair.com.

Cautionary Statement Concerning Forward-Looking Statements

Some of the statements, estimates or projections contained in this release are “forward-looking statements” within the meaning of the U.S. federal securities laws intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this release, including, without limitation, those regarding our business strategy, financial position, results of operations, plans, prospects, actions taken or strategies being considered with respect to our liquidity position, valuation and appraisals of our assets and objectives of management for future operations (including those regarding expected fleet additions, our voluntary suspension, our ability to weather the impacts of the COVID-19 pandemic and the length of time we can withstand a suspension of voyages, our expectations regarding the resumption of cruise voyages and the timing for such resumption of cruise voyages, the implementation of and effectiveness of our health and safety protocols, operational position, demand for voyages, financing opportunities and extensions, and future cost mitigation and cash conservation efforts and efforts to reduce operating expenses and capital expenditures) are forward-looking statements. Many, but not all, of these statements can be found by looking for words like “expect,” “anticipate,” “goal,” “project,” “plan,” “believe,” “seek,” “will,” “may,” “forecast,” “estimate,” “intend,” “future” and similar words. Forward- looking statements do not guarantee future performance and may involve risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from the future results, performance or achievements expressed or implied in those forward-looking statements. Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: the spread of epidemics, pandemics and viral outbreaks and specifically, the COVID-19 pandemic, including its effect on the ability or desire of people to travel (including on cruises), which are expected to continue to adversely impact our results, operations, outlook, plans, goals, growth, reputation, cash flows, liquidity, demand for voyages and share price; our ability to comply with the CDC’s Framework for

Conditional Sailing Order and to otherwise develop enhanced health and safety protocols to adapt to the current pandemic environment’s unique challenges once operations resume and to otherwise safely resume our operations when conditions allow; coordination and cooperation with the CDC, the federal government and global public health authorities to take precautions to protect the health, safety and security of guests, crew and the communities visited and the implementation of any such precautions; our ability to work with lenders and others or otherwise pursue options to defer, renegotiate or refinance our existing debt profile, near-term debt amortization, newbuild related payments and other obligations and to work with credit card processors to satisfy current or potential future demands for collateral on cash advanced from customers relating to future cruises; our potential future need for additional financing, which may not be available on favorable terms, or at all, and may be dilutive to existing shareholders; our indebtedness and restrictions in the agreements governing our indebtedness that require us to maintain minimum levels of liquidity and otherwise limit our flexibility in operating our business, including the significant portion of assets that are collateral under these agreements; the accuracy of any appraisals of our assets as a result of the impact of COVID-19 or otherwise; our success in reducing operating expenses and capital expenditures and the impact of any such reductions; our guests’ election to take cash refunds in lieu of future cruise credits or the continuation of any trends relating to such election; trends in, or changes to, future bookings and our ability to take future reservations and receive deposits related thereto; the unavailability of ports of call; future increases in the price of, or major changes or reduction in, commercial airline services; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; adverse incidents involving cruise ships; adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; any further impairment of our trademarks, trade names or goodwill; breaches in data security or other disturbances to our information technology and other networks or our actual or perceived failure to comply with requirements regarding data privacy and protection; changes in fuel prices and the type of fuel we are permitted to use and/or other cruise operating costs; mechanical malfunctions and repairs, delays in our shipbuilding program, maintenance and refurbishments and the consolidation of qualified shipyard facilities; the risks and increased costs associated with operating internationally; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our expansion into and investments in new markets; our inability to obtain adequate insurance coverage; pending or threatened litigation, investigations and enforcement actions; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; our inability to recruit or retain qualified personnel or the loss of key personnel or employee relations issues; our reliance on third parties to provide hotel management services for certain ships and certain other services; our inability to keep pace with developments in technology; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under “Risk Factors” in our most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the Securities and Exchange Commission. Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, the COVID-19 pandemic. It is not possible to predict or identify all such risks. There may be additional risks that we consider immaterial or which are unknown. The above examples are not exhaustive and new risks emerge from time to time. Such forward-looking statements are based on our current beliefs, assumptions, expectations, estimates and projections regarding our present and future business strategies and the environment in which we expect to operate in the future. These forward-looking statements speak only as of the date made. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in our expectations with regard thereto or any change of events, conditions or circumstances on which any such statement was based, except as required by law.

Investor Relations & Media Contact

Andrea DeMarco

(305) 468-2339 [email protected] Jessica John (786) 913-2902

MIAMI, Dec. 07, 2020 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today it has entered into a partnership (the “Agreement”) with Identity Key to provide blockchain based identity verification software for the medical industry. The Agreement calls for the Identity Based Plug-in to be integrated into Ehave’s Dashboard. Ehave will generate royalty revenue based on sales of identity verification software from Identity Key. Ehave currently has products in development that focus on telemedicine, providing medical data, and regulated substance research for mental health. Identity Key is a software company that focuses on creating verifiable credentials for users through the blockchain. Blockchain technology is creating huge opportunities for patients, doctors, and researchers to access data in new ways with audit trails and verifiable authentication.

“Online ID verification is seeing a spike in demand driven by the current pandemic. As many medical professionals send their staff to work remotely during the pandemic there has been a strong surge in demand for videoconferencing communication. Patient identification and verification is one of the most difficult issues the healthcare sector faces during these turbulent times, but it is critical in imparting fast and effective healthcare services to patients,” said Ben Kaplan, Chief Executive officer of Ehave. Mr. Kaplan continued, “Our research indicates digital identity verification systems can benefit healthcare providers by improving the quality of healthcare they provide. We see this opportunity to provide the blockchain based identity verification software from Identity Key to the medical industry as a means to enable them to improve organization and sharing of medical records, ensure insurance claims and reduce medical fraud by protecting patient data.”

According to MarketsandMarkets™ Research Private Ltd., “The post-COVID 19 global identity verification market size is expected to grow from USD 7.6 billion in 2020 to USD 15.8 billion by 2025, at a Compound Annual Growth Rate (CAGR) of 15.6% during the forecast period. The major factors fueling the identity verification market include increasing digitization initiatives, increase in fraudulent activities and identity theft during the last decade and increasing use cases of digital identities among verticals.”¹

“Making each person the center of their data has some exciting benefits,” said Adam Lambert founder of Identity Key. “Decentralized identity, puts patients in control of the entirety of their medical data, sharing only what is needed, when, and with whom.”

Identity Key technology provides a way to verify the source of information (Issuer) by establishing a unique, secure, direct line of communication between a data holder (Patient) and a data verifier (Recipient). This provides a layer of trust while preserving privacy and ensuring data protection.

Attestations about personally identifiable information are trusted, as they are digitally signed by a trusted issuer and can be verified cryptographically, without any data mediators.

Ehave plans to target patients, doctors, and researchers to help them quickly authenticate or release personal, verified data and give more control in situations where trust cannot be compromised. Utilizing the blockchain technology Ehave can offer its medical partners an opportunity to lower their administration costs by up to 90%. Ehave intends to offer its medical partners identity management solutions that include:

 – Verifying Patient Data prior to telemedicine.

 – Allowing the patient to control access to their medical files.

 – Allow partners to verify medical insurance faster.

 – Allow patients to share parts of their health information but maintain privacy.

By verifying patients, doctors, and medical partners faster and more securely, Ehave should be able to offer a significant savings on administration costs. This creates a very secure tool that ensures a more secure verification process and increase profits for medical professionals by lowering the cost of revenue.

Additional Ehave Inc. Statement

We are truly grateful for the patience and support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.

The company diligently posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit: www.ehave.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

For Investor Relations, please contact:

Gabe Rodriguez

Phone: (623) 261-9046

Email: [email protected]

<sup>____________________________

1</sup> https://www.marketsandmarkets.com/Market-Reports/identity-verification-market-178660742.html 

Founding Members Look to Provide Operators with Best Practices and Equipment in Raw Material Manufacturing

BUDAPEST, HUNGARY, Dec. 07, 2020 (GLOBE NEWSWIRE) — via NewMediaWire – Global Allied Processing Solutions (“G-APS” or “Organization”) today announced its strategic focus on the global organic material industry through its recent formation of an alliance representing companies on the forefront of technological advancements in processing equipment and practices. Founding members RotaChrom Technologies, the developer of the world’s first industrial-scale Centrifugal Partition Chromatography (CPC) technology platform, and Heidolph Instruments, the leader in the production of premium laboratory equipment, created G-APS to further establish best practices for the processing of raw materials through education and innovative equipment offerings.

RotaChrom and Heidolph formed G-APS through a shared vision and understanding of the global processing marketplace spanning several industries including pharmaceuticals, natural extracts, food and beverages, and cosmetics and fragrances. The Organization’s goal is to provide businesses with one-stop-shop access to multiple solutions for their processing and manufacturing infrastructure needs, with a specific focus on the extraction and purification of botanically-derived compounds and molecules. G-APS’ mission is to provide businesses with a vetted network of worldwide equipment suppliers that have proven results and work together seamlessly – avoiding potential overhead costs and risks when pairing machines that have not been previously tested in manufacturing settings.

“There are many nuances regarding equipment selection and production processes that must be taken into account when designing a fully functional processing facility,” said RotaChrom CEO László Madarász. “As operators in rapidly growing markets must navigate through an increasingly complex landscape to support their business’s success, we sought to build an alliance of vetted companies offering cutting-edge solutions to the processing segment of multiple industries’ supply chain.”

RotaChrom North America President Gyula Kangiszer stressed the importance of integrated solutions: “Customers face many challenges when trying to optimize ‘mix and match’ equipment. We are proud to provide a solution by combining our company’s technologies with other leading providers to create this much needed network.”

Founding companies RotaChrom and Heidolph are high-end equipment producers in the respective fields of purification and solvent recovery. The combination of the two founding members’ technologies resulted in a highly efficient system based on an optimized collaborative working principle that G-APS will expand upon with the addition of other member companies. To showcase the synergies between the companies’ equipment, the Organization in installing showrooms in multiple locations in Europe and North America. G-APS will announce more information when the installations are ready for public access.

“When we first paired our systems, we found that they were perfectly balanced and highly automated, allowing us to achieve increased throughput while providing unmatched quality results,” said Heidolph Instruments CEO Wolfgang Jaenicke. “We recognized that like-minded equipment companies should align to offer a full suite of resources to increase operational stability and find solutions in processing that allow greater capacity and automation, decrease costs, and increase output. Instead of operators being forced to piece together systems and test their efficiencies on a case-by-case basis, G-APS provides a coalition of equipment manufacturers whose technologies operate in tandem with one another. We hope to engage with other manufacturers who provide equipment for the processing phase of various supply chains, vet them on the basis of quality and safety, and build systems that are predetermined to give operators the ultimate result they are seeking.”

Heidolph North America President Jim Dawson added, “We are confident this value-add type of organization will not only be beneficial for our customers, but for the industry as a whole. Due to rising demand for more sophisticated solutions for separation, this partnership brings together two world class technologies resulting in an automated high precision separation for end users.”

G-APS aims to set standards for the processing industry as well as bring strategic cooperation, shared research and development, integrated project and sales activities, and value-add metrics needed for forward-thinking innovation. In addition to efficiency, the alliance is committed to bringing together systems that are flexible against the ever-changing regulatory and product landscape of the pharmaceutical, natural extract, food and beverage, and cosmetic and fragrance industries.

Global Allied Processing Solutions

Global Allied Processing Solutions (“G-APS”) is an international alliance of companies strategically focused on bringing leading solutions and best practices to the organic material industry. Its member companies are those on the forefront of technological advancements in processing equipment and practices that service several industries including pharmaceuticals, natural extracts, food and beverages, and cosmetics and fragrances. The goal of the alliance is to provide businesses with a singular platform comprised of multiple solutions for their processing and manufacturing infrastructure needs, with a specific focus on the extraction and purification of botanically-derived compounds and molecules. The G-APS mission is to provide operators with a vetted network of worldwide equipment suppliers that have proven results and work together seamlessly – avoiding potential overhead costs and risks when pairing machines that have not been previously tested in manufacturing settings. For more information, visit https://g-aps.com

RotaChrom Technologies

RotaChrom Technologies has developed the world’s first industrial scale Centrifugal Partition Chromatography (pCPC) technology platform with a fully automated solvent recycling system. The company’s instruments have revolutionized compound purification by providing cost-effective industrial scale chromatography solutions to customers all over the world in various industries including pharmaceutical, nutraceutical, food/beverage and botanical extracts. RotaChrom has achieved massive international success in pharmaceutical purification, and it has become an industry-leading company by setting global purification standards. RotaChrom’s CPC platforms are quintessential applications when looking for a high-purity, high-capacity, and yield-focused solution.

Heidolph Instruments

As an innovative and global corporation, we are a leader in the production of premium laboratory equipment. With our products and solutions, we support users in over 80 countries worldwide in their work. Every day, we contribute to improving the quality of life of many people. Heidolph Instruments devices and system solutions enable our customers to advance the healing and alleviation of disease. New techniques for ensuring adequate healthy foods are being developed with our products and new innovative materials can bring technological advances around the world. Other companies use our devices to manufacture, analyze; and ensure the quality of their products. Despite the wide variety of industries, all Heidolph customers have a certainty in common: they can always rely on the precision and reliability of our products. The combination of this outstanding quality with our world-leading service makes Heidolph Instruments one of the strongest partners in the laboratory equipment industry.

Media Contact:

Stephanie Plieness
CMW Media
858.264.6600
[email protected]

ATLANTA, Dec. 07, 2020 (GLOBE NEWSWIRE) — 2Checkout (now Verifone), the leading all-in-one monetization platform for global businesses, today announced that VS REVO Group – a utility software company – has considerably improved its eCommerce KPIs since switching to 2Checkout’s Avangate monetization platform.

The software company was lacking agility with its previous provider, with its eCommerce operation suffering in several areas including cart performance, technical support, and affiliate marketing. Since the switch, VS REVO Group has seen significant improvements in their digital commerce activity: a 63% improvement in cart conversion rate, and a 10% overall revenue uplift (estimated).

“Our onboarding with 2Checkout was seamless, support is very fast, and execution is impeccable. We were able to achieve in weeks and even days what in the past meant months. My team has been impressed with 2Checkout’s platform capabilities, especially the breadth and depth of subscription management and billing, which we are looking to fully leverage for our recurring business. Clearly, a beneficiary is our client base, that we can now serve in a seamless and modern way,” mentioned Tihomir Yordanov, Digital Marketing Manager at VS REVO Group.

“We are happy to have the opportunity to optimize digital commerce operations for VS REVO Group and help our client provide a better purchase experience for end-customers at a global level. At the same time, we are here to relieve clients like VS REVO Group of various privacy, sales taxation, and security regulations, enabling them to focus on interesting marketing, eCommerce, or retention campaigns. This is clearly helping them succeed and grow,” said Laurentiu Ghenciu, Global Vice President of Digital Business at Verifone.

For more information on the VS REVO Group success story, view the case study on the dedicated client page on the 2Checkout website.

About VS
REVO
Group

VS REVO Group Ltd., founded in 2007, is a software company that develops and manages various utility software products that streamline otherwise difficult processes for the average user. The group is best known for its REVO Uninstaller, a freeware-advanced uninstall utility. The VS REVO Group’s engineering team is recognized for its reliable and comprehensive new product development cycle, which includes assurance, testing, and debugging, as well as for its superior customer support.

More information on https://www.vsrevogroup.com/ and https://www.revouninstaller.com/

Ab
out 2Checkout
(now Verifone)

2Checkout (now Verifone) is the leading all-in-one monetization platform for global businesses built to help clients drive sales growth across channels and increase market share by simplifying the complexities of modern commerce. 2Checkout’s digital services, including global payments, subscription billing, merchandising, taxes, compliance and risk, help clients stay focused on innovating their products while delivering exceptional customer experiences.

In August 2020, leading global payments solution provider Verifone acquired 2Checkout, further solidifying its commitment to providing seamless and frictionless experiences to customers globally through innovative and next-generation hardware and cloud services. 2Checkout will become Verifone, and the unified company will enable omnichannel commerce wherever and whenever clients shop.

Get more information at www.2checkout.com.

Media Contact:
Delia Ene, 2Checkout
Email: [email protected] 
Tel: +31 20 890 8080 ext.: 4654

• Phase 3 trials’ topline data anticipated in the first quarter of 2021 and potential New Drug Application (NDA) submission anticipated by the end of 2021
• Roflumilast cream potential “Best in Class” topical PDE4 inhibitor
• Plaque psoriasis affects approximately 8.6 million patients in the U.S.

WESTLAKE VILLAGE, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that the last participant has completed the 8-week treatment period in DERMIS-1 and DERMIS-2, the Company’s pivotal Phase 3 clinical trials evaluating ARQ-151 (topical roflumilast cream) as a potential topical treatment for plaque psoriasis.

“Plaque psoriasis affects approximately 8.6 million patients in the U.S., many of whom are desperate for new topical options that don’t require them to make trade-offs,” said Patrick Burnett, M.D., Ph.D., FAAD, Arcutis’ Chief Medical Officer. “We are delighted to complete DERMIS-1 and DERMIS-2, our pivotal phase 3 clinical trials evaluating roflumilast cream as a potential once daily topical treatment for plaque psoriasis. If approved, we believe roflumilast cream has the potential to eliminate the need for dermatologists and patients to compromise between efficacy and safety. We anticipate announcing topline data from these trials in the first quarter of 2021 and, if positive, anticipate submission of our NDA to the FDA by the end of 2021. We are immensely grateful to the trial participants and the clinical investigators for their time and commitment to this important research effort.”

Arcutis recently announced positive results from its Phase 2 long-term safety study in plaque psoriasis, which support chronic use of roflumilast cream. In addition, The New England Journal of Medicine published results from the double-blind, randomized Phase 2b study of roflumilast cream in plaque psoriasis.

The “Trials of PDE4 inhibition with Roflumilast for the Management of plaque PsoriasIS” One and Two (or DERMIS-1 and DERMIS-2) are identical Phase 3 randomized, parallel, double-blind, vehicle-controlled, multi-national, multi-center studies in which roflumilast 0.3% cream or vehicle cream are applied once daily for 8 weeks to subjects age 2 years and above with mild, moderate or severe chronic plaque psoriasis involving between 2% and 20% body surface area. DERMIS-1 enrolled 439 subjects, and DERMIS-2 enrolled 442 subjects. The primary endpoint of the studies is Investigator Global Assessment (IGA) Success, defined as an IGA score of clear or almost clear and at least a 2-grade improvement from baseline at week 8 on the IGA score. Multiple secondary endpoints will also be evaluated, including Intertriginous IGA (I-IGA) Success, and improvements in Psoriasis Area Severity Index (PASI), itch as measured by the Worst Itch-Numerical Rating Scale (WI-NRS) and patient perceptions of symptoms as measured by the Psoriasis Symptoms Diary (PSD). The Company anticipates topline data from the Phase 3 studies in the first quarter of 2021 and, if positive, anticipates submission of its NDA to the FDA by the end of 2021.

About
Topical Roflumilast Cream

Roflumilast Cream is a topical cream formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has been approved by the U.S. Food and Drug Administration (FDA) for oral treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD) since 2011. Roflumilast has shown greater potency (25- to 300-fold) than the two other FDA-approved PDE4 inhibitors. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and COPD. PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical treatment of atopic dermatitis or the systemic treatment of plaque psoriasis.

About Psoriasis

Psoriasis is a common, non-contagious, immune-mediated skin disease that affects approximately 8.6 million patients in the United States. About 90% of patients develop plaque psoriasis, which is characterized by raised, red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and are often itchy and sometimes painful. Plaques in certain anatomical areas present particular treatment challenges, including the face, elbows and knees, scalp, and intertriginous regions such as the groin, axillae and inframammary areas.

About Arcutis
– Bioscience, applied to the skin.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.

Forward Looking Statements

This press release contains “forward-looking” statements, including, among others, statements regarding roflumilast cream’s potential as a psoriasis treatment; and expectations with regard to the timing of clinical data anticipated in the first quarter of 2021 and NDA submission by the end of 2021. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-Q filed with U.S. Securities and Exchange Commission (SEC) on November 5, 2020, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contact
:

Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
[email protected]
805-418-5006, Ext. 740

Lake Forest , Calif, Dec. 07, 2020 (GLOBE NEWSWIRE) — ToughBuilt Industries, Inc. (“ToughBuilt”) (NASDAQ: TBLT; TBLTW), today announced the launch of soft sided tool organization products, consisting of 4 hard body bags, 10 CLIPTECH™ pouches and accessories, at LOWE’S stores nationwide & LOWE’S.com.

Michael Panosian, Chief Executive Officer of ToughBuilt, stated, “These are the best in category products that will set the market standard for performance. I am proud of our tough team that has worked tirelessly to develop this complicated product line and delivered in record time. Please see Massive Mouth Bag video here & CLIPTECH™ video here.

We are grateful for this opportunity with LOWE’S and looking forward to strengthening our partnership as we continue to design, manufacture, and offer top quality innovation to the professional and passionate builders at LOWE’S.

ABOUT TOUGHBUILT INDUSTRIES, Inc.

ToughBuilt Industries, Inc. is an advanced product design, manufacturer and distributor with emphasis on innovative products. Currently focused on tools and other accessories for the professional and do-it-yourself construction industries. We market and distribute various home improvement and construction product lines for both the do-it-yourself and professional markets under the TOUGHBUILT brand name, within the global multibillion dollar per year tool market industry. All of our products are designed by our in-house design team. Since launching product sales in 2013, we have experienced significant annual sales growth. Our current product line includes three major categories, with several additional categories in various stages of development, consisting of Soft Goods & Kneepads and Sawhorses & Work Products. Our mission is to provide products to the building and home improvement communities that are innovative, of superior quality derived in part from enlightened creativity for our end users while enhancing performance, improving well-being and building high brand loyalty. Additional information about the Company is available at: https://www.toughbuilt.com.

FORWARD-LOOKING STATEMENTS:

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) delays in bringing products to key markets, (iii) an inability to secure regulatory approvals for the ability to sell our products in certain markets, (iv) intense competition in the industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) our reliance on single suppliers for certain product components, (x) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xi) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Relations Contact:

Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
[email protected]

Attachment

• ToughBuilt Industries, Inc.

FOREST HILL, Md., Dec. 07, 2020 (GLOBE NEWSWIRE) — Since 2014, The International Society for the Study of Trauma and Dissociation (ISSTD) has used CadmiumCD’s myCadmium Event Management Platform to collect, manage, and share content for its annual and regional conferences and trade shows. Today, ISSTD expands its capabilities by bringing on CadmiumCD sister company, EthosCE, as its Learning Management System for all continuing education programs.

“ISSTD’s annual and regional conferences are only one facet of their organization’s continuing education activities,” says Raja Venkata, EthosCE Director of Client Services. “EthosCE adds to ISSTD’s capabilities by enabling them to deliver year-round education to their members.”

The addition of EthosCE to their current technology stack empowers ISSTD to manage and deliver the following:

• A personalized, intuitive learning dashboard
• Mobile grand rounds/RSS attendance tracking
• Persistent transcript records of all completed activities regardless of the year
• Support for unlimited credit types – Personalized learner transcripts, credit tracking and certificates
• Live event management
• Single-sign-on integration
• Robust assessment instruments
• ACCME compliant PARS and JA-PARS reporting

When parent company, Symphony Technology Group (STG) announced the acquisition of EthosCE, William Chisholm, co-founder and Managing Partner of STG, said, “The acquisitions of EthosCE and CadmiumCD mark the beginning of a very exciting journey for STG and the two companies. Our vision is to create a purpose-built software platform for association, healthcare, life sciences and university customers to help them manage various continuing education, professional development and learning activities, events and content for their members.”

ISSTD’s implementation of both CadmiumCD and EthosCE platforms is yet another step toward this vision of a unified software platform for education management.

About CadmiumCD

CadmiumCD is an event management software company with more than 20 years of experience providing solutions for Meeting Planners, Exhibition Organizers, Education Directors, and Attendees. The company’s award-winning platform is trusted by more than 3,500 meeting professionals worldwide to collect, manage and share content to all event stakeholders.
For more information, visit www.cadmiumcd.com or call 1-877-426-6323.

About EthosCE

EthosCE
is the leading learning management system for medical associations, academic medical centers, health systems, and medical education companies produced by DLC Solutions, LLC. Established in 2001, DLC Solutions develops innovative e-learning solutions to support diverse professional populations.
For more information, please visit www.ethosce.com

About ISSTD

The International Society for the Study of Trauma and Dissociation represents mental health professionals who specialise in treating complex trauma and dissociation. The ISSTD’s membership includes more than 1,500 clinicians and researchers. The ISSTD seeks to advance clinical, scientific, and societal understanding about the prevalence and consequences of complex trauma and dissociation.

Michael Doane, Marketing Manager, [email protected]

• Covid-19 Rapid Antibody Tests have FDA Permission under EUA for sale & distribution in the United States and CE Designation for sale & distribution throughout the European Union
• Covid-19 Rapid Antigen Tests come with the CE Designation for sale & distribution throughout the European Union
• These agreements will increase production capacity, shorten delivery times, and be available at a reduced cost
• The Company will be able to offer White Label Covid-19 Rapid Testing Kits and the new packaging options will allow for Covid-19 Rapid Tests to be sold in packages of 10, 25 and 50 units
• This agreement will immediately alleviate any supply chain problems from the Company’s current Rapid Testing products made in Brazil

VANCOUVER, British Columbia, Dec. 07, 2020 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or the “Company“) (CSE:VST) (OTC:VSQTF) (FWB:6F6) — has entered into two Manufacturing, Sales and Distribution Agreements to supply White Label Covid-19 Rapid Antibody and Antigen Tests to be distributed through the company’s global distribution network, as well as sold online through the company’s ecommerce channels.

The agreements will also supply Victory Square with access to manufacture, sell and distribute other White Label diagnostic tests that will be available on the Company’s telehealth platform to be launched shortly.

The Covid-19 Rapid Antibody Tests have FDA Permission under EUA for sale & distribution in the United States and the CE Designation for sale & distribution throughout the European Union. The Covid-19 Rapid Antigen Tests come with the CE Designation for sale & distribution throughout the European Union.

These agreements will alleviate the supply and packaging challenges the company is currently facing due to the high demand for the company’s Safetest Rapid Tests in the country of origin – Brazil.

Highlights of these agreements include:

• Increased production capacity
• Quicker manufacturing & delivery turn-around times
• Lower prices for industrial and retail sales
• The new packaging will allow for Covid-19 Rapid Tests to be packaged in 10, 25 and 50 units

“These new supply channels will allow us to increase capacity, improve turn-around times, and lower costs by approximately 30%” said Shafin Diamond Tejani, CEO. Tejani goes on to say, “Victory Square has built up a global sales network over the past couple of months. These new manufacturing agreements will eliminate the supply bottleneck and enable the company and its agents to continue selling the Covid-19 Rapid Tests.”

The Covid-19 Rapid Tests being supplied to fulfill current orders have FDA EUA permission and the CE Designation from EU authorities for sale. There will not be any disruption to the company’s current demand for tests. The Company has also created its own Private Label brand of tests. Victory Square Health is voluntarily updating and resubmitting the new packaging and design specifications of their Rapid Test to the FDA.

“ProNorth Medical is very pleased with this new label from Victory Square. Our clients have been requesting quicker turnaround times, different quantity options and access to both antibody and antigen rapid tests. Now we will be able to offer options to them. We couldn’t be happier,” said Robert Horne, ProNorth Medical CEO.

Disclaimer:

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time

Check out VictorySquare.com and sign up to VST’s official newsletter at



www.VictorySquare.com/newsletter

On behalf of the board,

Shafin Diamond Tejani

Chief Executive Officer

Victory Square Technologies

For further information about the Company, please contact:

Investor Relations Contact – Alex Tzilios

Email: [email protected]

Telephone: 778-867-0482

Media Relations Contact – Howard Blank, Director

Email: [email protected]

Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.

Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth.

VST’s sweet spot is the cutting-edge tech that’s shaping the 4th Industrial Revolution. Our portfolio consists of 20 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups

VST isn’t just another investor. With real skin in the game, we’re committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you’ll scale and be ready to monetize.

What we do differently for investors

VST is a publicly traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).

For investors, we offer early-stage access to the next unicorns before they’re unicorns.

Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies while also tapping into emerging global trends with big upsides. For more information, please visit www.victorysquare.com.

Forward Looking Statement

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

San Diego, California, Dec. 07, 2020 (GLOBE NEWSWIRE) — Tesoro Enterprises, Inc. (OTCMKT: TSNP) issued a statement today reminding shareholders and investors that HUMBL will be hosting an investor call on December 9, 2020 at 5:00 p.m. on the Zoom app. Prospective attendees must be registered for the call through the website

www.HUMBLpay.com
. All registrations must be received by 5:00 p.m. today, Monday, December 7.

During the call, attendees will be introduced to HUMBL President and CEO, Brian Foote, who will discuss HUMBL’s technologies, business model and roadmap for the upcoming year. HUMBL’s Corporate Advisor, George Sharp, will briefly discuss the merger with Tesoro Enterprises and the processes which remain to be executed. There will be no discussion regarding stock performance or structure.

Registered attendees will receive an emailed link to the call during the evening of December 7. Attendees will be muted throughout the call. A limited number of questions will be answered during the call. Those registered attendees wishing to submit questions for the call, may email them to [email protected] and must enter “Investor Call Question” into the subject line of the email. Attendee questions must be received by 5:00 p.m. on Tuesday, December 8, in order to be considered for address. Again, any questions regarding stock performance will not be entertained.

About HUMBL^®

The mission of HUMBL^® and HUMBL Hubs^™ is to deliver high quality, low cost digital payments and financial services. The HUMBL network was designed to support vertical markets such as government, banking, wireless and merchants in locations like Latin America, Caribbean, Asia and Africa who are seeking to migrate to digital payment and financial technologies, to help reduce costs and improve settlement speeds for customers.

The HUMBL^® Mobile App delivers borderless transactions, by integrating multiple currencies, payment methods, banks, blockchain and financial services providers into one-click for the customer. HUMBL^® provides greater access and portability than US only mobile wallet providers, such as Venmo^® and Zelle^® and will offer a HUMBL Hubs^™ merchant software for clients without smartphones in certain domiciles.

“We aren’t building HUMBL for the 350 million customers using PayPal^®, but for the 7 billion people for whom money moves in different pathways, formats and cost structures,” according to the CEO of HUMBL, Brian Foote.

The HUMBL website features global brand videos, product tours, market research, white papers and network architecture at www.HUMBLpay.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company’s ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company’s control.

CONTACT:

HUMBL, LLC
[email protected]